BioSig Installs PURE EP(tm) System at Massachusetts General Hospital
August 04 2020 - 9:25AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”), a medical technology company developing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the Company installed its PURE EP(tm)
System at Massachusetts General Hospital (MGH) as part of an
expanding clinical study.
The PURE EP(tm) System evaluation and data collection at MGH
will commence under the leadership of investigator Moussa Mansour
M.D., Director of MGH’s Cardiac Electrophysiology Laboratory
and Atrial Fibrillation Program.
“Bringing our technology to a major EP institution on the east
coast is a definite milestone in our clinical development. We look
forward to working with Dr. Mansour and the entire MGH team as we
pursue our mission of bringing advanced signal processing solutions
to the field of electrophysiology,” commented Kenneth L. Londoner,
Chairman, and CEO of BioSig Technologies, Inc.
BioSig is currently conducting patient cases under the clinical
study titled, “Novel Cardiac Signal Processing System for
Electrophysiology Procedures (PURE EP 2.0 Study)” at Texas Cardiac
Arrhythmia Research Foundation (TCARF) in Austin, Texas and Mayo
Clinic in Jacksonville, Florida.
The Shareholder Letter issued by the Company on April 17, 2020,
announced that it received Institutional Review Board approvals to
install its PURE EP(tm) System at several medical centers across
the country for evaluation. All of these centers are high-volume
clinical sites regarded for their work with new technologies.
“The market for atrial fibrillation is starting to open up again
as patient cases are crucial for healthcare outcomes”, said
Londoner.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve
signal fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP (tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (ii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iii)
difficulties in obtaining financing on commercially reasonable
terms; (iv) changes in the size and nature of our competition; (v)
loss of one or more key executives or scientists; and (vi)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024